REYKJAVIK, Iceland, Jan. 18 /PRNewswire-FirstCall/ -- Through deCODEme(TM), the world's first retail genome analysis service, deCODE genetics (Nasdaq: DCGN) today announced the launch of the first focused genetic scans for assessing personal risk of several major cardiovascular diseases and common cancers. deCODEme Cardio(TM), which detects genetic risk factors for heart attack, stroke and atrial fibrillation, peripheral artery disease (PAD), and several other conditions, is offered at an introductory price of $195. deCODEme Cancer measures genetic risk factors for prostate, lung, bladder, skin and colorectal cancers, as well as the common form of breast cancer, at an introductory price of $225. Both can be ordered as a bundle for $350. Detailed information on what the scans measure and how to order can be found at www.decodeme.com/cardio and www.decodeme.com/cancer.
"The common diseases, including cardiovascular conditions such as heart
attack and stroke, as well as the common forms of cancer in women and men,
result from both genetic and environmental risk factors. We are all familiar
with many of the environmental and lifestyle factors that impact our risk of
these diseases, and we know that addressing these risk factors can lower our
risk of disease. Building on our discoveries of inherited risk factors for
these diseases, our goal is to help individuals understand the genetic side of
the equation. This is empowering information, that may enable people, on their
own or working with their doctors, to make more informed decisions to protect
their health. In an age when we are encouraged to take more responsibility for
our health, we believe that we should all be able to use understanding of our
genome to do
Copyright©2009 PR Newswire.
All rights reserved